Significant Clinical Progress Across Target Indications during 2019 and 2020 Year-to-Date Interim Phase II bullous pemphigoid (BP) data demonstrated a rapid …
Press Release
Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement
NEW YORK and LONDON, March 4, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to …
[Read more...] about Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement
Akari Therapeutics, Plc Announces Private Placement
NEW YORK and LONDON, February 20, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative …
[Read more...] about Akari Therapeutics, Plc Announces Private Placement
Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases
The new data show PAS-nomacopan (the long acting form of Akari’s lead drug, nomacopan) significantly reduced VEGF levels and retinal inflammation, both of which …
Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study
All patients treated with nomacopan have achieved the primary endpoint of transfusion independence Phase III interim data on the first eight PNH patients …
